ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,667.56
0.08%
Dow Jones
41,985.35
0.08%
US Dollar vs MXN
20.2392
0.48%
Brent Oil
71.775
-0.13%
Bitcoin
84,082.18
-0.06%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. NeuroSense Therapeutics Ltd (NRSN) Cotización

NeuroSense Therapeutics Ltd

NeuroSense Therapeutics Ltd (NRSN)

NASDAQ
1.07
0.0026
(0.24%)
Al cierre: 21 Marzo 2:00PM
Delayed by 15 minutes
1.07
0.00
( 0.00% )
Fuera de horario: 4:24PM
Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Estadísticas y detalles clave

Último Precio
1.07
Postura de Compra
1.01
Postura de Venta
1.07
Volume Operado de la Acción
118,138
1.03 Rango del Día 1.10
0.512 Rango de 52 semanas 2.25
Capitalización de Mercado [m]
20.833M
Precio Anterior
1.0674
Precio de Apertura
1.10
Hora
1
@
1.06
Última hora de negociación
16:30:09
Volumen financiero
US$ 124,372
Precio Promedio Ponderado
1.0528
Volumen promedio (3 m)
157,915
Acciones en circulación
19,470,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.38
Beneficio por acción (BPA)
-0.58
turnover
-
Beneficio neto
-11.28M

Acerca de NeuroSense Therapeutics Ltd

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among... NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.neurosense-tx.com
Sede
Herzliya, Center, Isr
Fundado
-
NeuroSense Therapeutics Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NRSN. The last closing price for NeuroSense Therapeutics was US$1.07. Over the last year, NeuroSense Therapeutics shares have traded in a share price range of US$ 0.512 to US$ 2.25.

NeuroSense Therapeutics currently has 19,470,000 shares in issue. The market capitalisation of NeuroSense Therapeutics is US$20.78 million. NeuroSense Therapeutics has a price to earnings ratio (PE ratio) of -0.38.

NRSN Últimas noticias

Más noticias
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.07-6.140350877191.141.231.00012795801.12977515CS
4-0.06-5.309734513271.131.230.96331594891.10676159CS
12-0.16-13.00813008131.231.330.96331579151.1251533CS
26-0.22-17.05426356591.291.420.82237061.14912209CS
52-0.74-40.88397790061.812.250.5122428091.09517919CS
156-1.11-50.91743119272.188.180.49485863.41187144CS
260-3.48-76.48351648354.558.180.49201753.3653659CS

NRSN - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de NeuroSense Therapeutics?
El precio actual de las acciones de NeuroSense Therapeutics es US$ 1.07
¿Cuántas acciones de NeuroSense Therapeutics están en circulación?
NeuroSense Therapeutics tiene 19,470,000 acciones en circulación
¿Cuál es la capitalización de mercado de NeuroSense Therapeutics?
La capitalización de mercado de NeuroSense Therapeutics es USD 20.78M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de NeuroSense Therapeutics?
NeuroSense Therapeutics ha negociado en un rango de US$ 0.512 a US$ 2.25 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de NeuroSense Therapeutics?
El ratio precio/beneficio de NeuroSense Therapeutics es -0.38
¿Cuál es la moneda de reporte de NeuroSense Therapeutics?
NeuroSense Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de NeuroSense Therapeutics?
El último beneficio anual de NeuroSense Therapeutics es USD -11.28M
¿Cuál es la dirección registrada de NeuroSense Therapeutics?
La dirección registrada de NeuroSense Therapeutics es MEDINAT HA-YEHUDIM STREET, 85, HERZLIYA, CENTER
¿Cuál es la dirección del sitio web de NeuroSense Therapeutics?
La dirección del sitio web de NeuroSense Therapeutics es www.neurosense-tx.com
¿En qué sector industrial opera NeuroSense Therapeutics?
NeuroSense Therapeutics opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
IMTEIntergrated Media Technology Ltd
US$ 0.8001
(48.19%)
1.32M
TCBPTC BioPharm Holdings PLC
US$ 0.723
(44.60%)
3.86M
BSGMBioSig Technologies Inc
US$ 0.7428
(36.27%)
125.15k
WINTWindtree Therapeutics Inc
US$ 1.73
(16.89%)
1.18M
RGCRegencell Bioscience Holdings Ltd
US$ 68.20
(16.32%)
60.39k
NVNINVNI Group Ltd
US$ 0.1748
(-28.01%)
3.6M
LGHLLion Group Holding Ltd
US$ 0.0789
(-20.78%)
588.61k
GNLNGreenlane Holdings Inc
US$ 0.3465
(-18.95%)
116.05k
QVCGBQVC Group Inc
US$ 5.50
(-16.92%)
496
SHFSSHF Holdings Inc
US$ 0.2619
(-14.44%)
13.89k
DMNDamon Inc
US$ 0.0377
(1.07%)
19.24M
CSCOCisco Systems Inc
US$ 60.1877
(-0.19%)
8.2M
SGLYSingularity Future Technology Ltd
US$ 1.5407
(-8.29%)
7.43M
YHCLQR House Inc
US$ 0.4568
(14.20%)
6.6M
NVDANVIDIA Corporation
US$ 117.66
(-0.03%)
6.01M

NRSN Discussion

Ver más
runncoach runncoach 1 mes hace
Volume firming up with price. Maybe we'll get partnership details to push this above 2 bucks while we await P3 launch this summer.
👍️0
runncoach runncoach 2 meses hace
If the company has to do another bridge money raise until a partnership, the recent filings of the last money raise likely show the reason the price remains so low IMO. The "most favored nations" clause tends to cap the share prices. That's besides the millions of warrant shares. Hopefully a buck and change holds.
👍️0
runncoach runncoach 2 meses hace
Folks should be careful. If they don't get things finalized we could be looking at a reverse split. Partnerships don't always work out. Regardless, no sales in 2025 but hopefully they launch the P3 this summer as they project.
👍️0
runncoach runncoach 2 meses hace
I told folks to be careful and not listen to the pump. If they don't get things finalized we could be looking at a reverse split
👍️0
johnhancoque johnhancoque 2 meses hace
Just gained nasdaq compliance and now threatening it. If anything, this is an emberassing complication for the ceo. Something needs to change here because the hedge funds are clearly in violation of manipulating the share price. The market cap is only 19 million. The ceo needs to up his game and get some positive pr happening or these guys will continue to manipulate the share price every day
👍️0
runncoach runncoach 3 meses hace
Apparently you don't follow but all good. I wasn't the one pumping 7.50 or 12 bucks and similar or pretending management bought 1.25 shared without mentioning the additional 8 million warrant shares. I read the financials. Most don't. Going to be a trading stock for a couple years IMO. Not much to see in 2025 but happy for the company and hope for the patients which is the most important thing and today progress was certainly made.

Very happy to see they are getting a partnership and have an avenue to begin their P3 next summer. Reminds me of the partnership for Neuren Pharma years back for Rett Syndrome although they treat a variety of underserved indications as well. If the drug works we should know maybe 2027. Hopefully longs will see a pay day down the road. Maybe something pans out with Canada in 2026.
👍️0
johnhancoque johnhancoque 3 meses hace
Um...when was it approved? Blockbuster status won't be known until it's selling around the world, which won't be hard now with Big Pharma backing them. Your understanding of bios is very limited. Widen your horizons and stop wasting your time here as what you post makes very little sense anyways
👍️0
runncoach runncoach 3 meses hace
Must have not been blockbuster, eh?
👍️0
johnhancoque johnhancoque 3 meses hace
https://finance.yahoo.com/news/neurosense-therapeutics-enters-binding-term-140000065.html
👍️0
johnhancoque johnhancoque 3 meses hace
Nobody claims a multibillion dollar partnership. Read the headlines. They are in discussions with several multi- billion dollar companies for partnerships. Also, they could have done a large public offering to keep the lights on as they are nasdaq listed. Instead the ceo chose to do a private placement and buy 5 million worth. The partnerships are for funding the continued trials and I know alot about how things work with pharma as I've been trading bios 20 years. The data is impressive and worth Billions and as the market catches on expect significant rises in the share price
👍️0
runncoach runncoach 3 meses hace
How much do you think a P3 cost? That's why so little leverage. Why didn't they already get a partnership they've talked about for 4 months? It's not easy when you don't have cash. It's not going to be a multi billion partnership that I've seen some posting about. Ceo kept them listed and gave a couple months breathing room. Congrats to him
👍️0
johnhancoque johnhancoque 3 meses hace
Right. You believe he did it to keep the lights on when he could have done a public offering for alot more. Instead, he spent 5 million of his own money suggesting he has faith in a very large partnership. Your way of thinking is twisted. No need reply again
👍️0
runncoach runncoach 3 meses hace
I'm suggesting he bought to keep the company's listing and float the company til they find funding since they can't fund a P3 trial. It's not a strong position to negotiate from. I don't think I'm saying anything controversial or that isn't common sense at this point. I expect them to find something and then there will be a very long wait
👍️0
johnhancoque johnhancoque 3 meses hace
You're suggesting the ceo bought 5 million worth of stock this month well above market value because he may not succeed in finding a partner? That sounds ridiculous buddy. It's more likely he is very confident in finding a partnership or is in the final stages so he bought 5 million worth. Your understanding of how insiders buys shares is out to bloody lunch. Hardly anyone would spend 5 million on a single stock without a near sure bet let alone a ceo of a publicly traded company
👍️0
johnhancoque johnhancoque 3 meses hace
A ceo who had no faith in a partnership sure as he'll wouldn't pony up 5 million bucks if there was nothing in the works. Don't miss the forest for the trees. He bought 5 million worth because a partnership is in the works.
Smh
👍️0
runncoach runncoach 3 meses hace
Been here long before you. Ceo ponied up money to meet Nasdaq requirements. Stock got shorted down so the "raise" price would look better.

Doesn't take a genius to realize not having the cash to even make it to the start of launching a P3 next summer isn't negotiating from a position of strength. If they don't get a partnership there would have to be a very unfavorable money raise to launch the trial. Between a rock and a hard place as far as negotiating.

Let's hope they get a partnership on favorable terms and a nice spike before the stock pulls back with the markets realizing another 12+ months til Canadian news and much longer than that for US.
👍️0
johnhancoque johnhancoque 3 meses hace
So now and ceo who buys 5 million worth of stock isn't a good sign, it's a bad sign of a pump? Where do you guys come from, really?
Even with good news you shorts twist things unrecognizable. Truly unbelievable
The ceo bought 5 million worth 30% above the then market price. They don't need cash they need a partnership which they will have no problem finding and are in discussions right now with several Big Pharmas. Drugs like this don't go unnoticed long with Big pharma sniffing around. Just sell and get lost because your comments are useless to the investing community
👍️0
runncoach runncoach 3 meses hace
Was wondering about the pump.

Folks will soon learn you don't get billion dollar partnerships when the CEO is having to buy stock to keep the lights on I'm afraid. Give me 3 bucks and I'll sit this one out for a while.
👍️0
johnhancoque johnhancoque 3 meses hace
$7.50 Cantor price target 🥱👀
👍️0
runncoach runncoach 3 meses hace
Not immediately it won't, no. Not in a price sustainable way that is. I own shares but will sell any significant spikes and buy back lower to hold long term
👍️0
johnhancoque johnhancoque 3 meses hace
You don't understand. A partnership with BP takes NRSN to the next level no looking back. Once a partnership is announced with a large upfront payment, there will be no looking back for this company, ever. It will be bought by BIg Pharma long before p3 results. Easy to manufacture and worldwide protection until 2044
👍️0
runncoach runncoach 3 meses hace
The problem is there is a large number of warrant shares available that will keep a lid on the share price after any spikes. Company has low funds considering it has yet to begin their P3. Sales are 2-3 years away at the least. Details of any partnership will be very important concerning future potential money raises. Sell significant spikes is my advice because folks sitting on warrants likely will. JMHO
👍️0
johnhancoque johnhancoque 3 meses hace
$9.25 price target. Partnership news looks imminent. Only 25 million market cap has 400% to run at a minimum here
👍️0
johnhancoque johnhancoque 3 meses hace
CEO bought 5 million worth and no matter how you spin that it will always be a boon for the company and shareholders. Regardless of what you say, any ceo who puts up 5 million bucks and above market for that matter says everything about where the sp is headed nearterm and speaks volumes about the confidence he has in his company and the data. Simple as that!
👍️0
McMagyar McMagyar 3 meses hace
Except
The value would have already rocketed well past $1.25.. with so few shares out.. and after the news hit, the company could have raised the same amount of money by issuing fewer shares, less dilution, shares more valuable.. now only one shareholder benefits from knowing the good news.. sure looks like a shareholder lawsuit to me.. greed sucks.. maybe the other shareholders will let it go.. maybe they won't..
You can't control what happens, but you can control with whom you do bizness..
Thx Barrister.. wise words
👍️0
johnhancoque johnhancoque 3 meses hace
All that matters is he bought 5 million shares @ $1.25 and the share price is about to rocket hard. Analysts price targets north of $12.00
👍️0
McMagyar McMagyar 3 meses hace
This smells a lot like stealing to me..
All the other shareholders got diluted.. while the sole stock buyer of issuance becomes kazillionairre.. sounds like an attorney would want to know what the shareholder who bought all this stock knew.. and why the offering wasn't made to other shareholders?
👍️0
johnhancoque johnhancoque 3 meses hace
Insider trading doesn't mean insiders can't buy shares or participate in offerings. There are however windows they have to abide by and if a significant partnership is announced in January they are well within their time to buy shares
👍️0
johnhancoque johnhancoque 3 meses hace
Insider trading doesn't mean insiders can't buy shares or participate in offerings. There are however windows they have to abide by and if a significant partnership is announced in January they are well within their time to buy shares
👍️0
runncoach runncoach 3 meses hace
That would look quite a bit like inside trading if they did that the next couple months. Trust me I hope so but doesn't look good to me.
👍️0
johnhancoque johnhancoque 3 meses hace
$25.00 with partnership and large upfront payment
👍️0
johnhancoque johnhancoque 3 meses hace
Um....he sold himself the last offering because there is a multi Billion dollar partnership about to be signed
👍 1
McMagyar McMagyar 4 meses hace
It was a money raise to one guy.. total bullshit. Thief
👍️0
runncoach runncoach 4 meses hace
The issue to me is the stock was sold down the last 2 or 3 weeks on "no news" and then we get a low price money raise. Doesn't look good
👍️0
McMagyar McMagyar 4 meses hace
Co issues 12,000,000 share rights to one guy right before good news hits?  What a legal Scally wag.. what's to stop him from issuing himself another 10,000,000?  Know them but their greed.
What a crock
👍️0
runncoach runncoach 4 meses hace
Today's PR would certainly lead one to believe no partnership type of completion until next year at the earliest IMO
👍️0
runncoach runncoach 4 meses hace
Just under 21 million
👍️0
BurgerKing82 BurgerKing82 4 meses hace
What's OS now?
👍️0
runncoach runncoach 7 meses hace
From this evening's 6K. No idea if it's BS or not.
NeuroSense Therapeutics Ltd. (the Company) hereby reports that it is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership for the development and commercialization of its lead drug candidate, PrimeC, for the treatment of Amyotrophic Lateral Sclerosis (ALS).



These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, milestone payments and royalty payments as part of an agreement. NeuroSense anticipates receiving terms from these discussions in Q4 2024; however, there can be no assurance that terms will be finalized with any of the pharmaceutical companies, the timing, what would be the final terms, if any, or that a definitive agreement will be reached.
👍️0
runncoach runncoach 7 meses hace
Money raise with .75 warrants attached fyi. Now we know why the price has remained so low IMO
👍️0
vein vein 8 meses hace
Thanks much for the insight !
👍️0
runncoach runncoach 8 meses hace
Who knows? Unless you are trading the stock, real results are a long ways off IMO and that can lead to opportunity cost. If it's a small percentage of a speculative portfolio the current price probably isn't bad. Just depends on your patience level
👍️0
vein vein 8 meses hace
Why the sell off ?? Thanks in advance!
👍️0
vein vein 8 meses hace
Seems like a decent entry ?
👍️0
runncoach runncoach 8 meses hace
The data is good but they'll have to raise money for a P3 so these guys are still a ways off IMO. They've mentioned a potential Biogen partnership last year yet here we stand. I do believe the drug is safe and has a real chance. Timing is everything.
👍️0
vein vein 8 meses hace
Time to buy now ??? Newbie here! Any thoughts ??
👍️0
Monksdream Monksdream 8 meses hace
NRSN under $2
👍️0
runncoach runncoach 9 meses hace
Great data out. On to P3. Only thing that will likely sustain share price after this rally is partnership IMO.
👍️0
Awl416 Awl416 9 meses hace
Don’t blink
👍️0
runncoach runncoach 10 meses hace
Certainly showing a positive trend on the scientific front.
https://ih.advfn.com/stock-market/NASDAQ/neurosense-therapeutics-NRSN/stock-news/93791685/neurosense-announces-new-positive-data-analysis-fr
👍️0

Su Consulta Reciente

NASDAQ
NRSN
NeuroSense Therapeutics
BITMOT
874809
Austria Tf 0% Ot40 Eur
USOTC
FNMA
Fannie Mae (QB)
COIN
ATRUSD
AsterionWorldToken
HUOB
SWRVBTC
Swerve DAO Token
NASDAQ
DSGN
Design Therapeutics
COIN
NIOGBP
Autonio
BOV
PSSA3
PORTO SEGURO ON
COIN
XMXGBP
XMax
USOTC
ABBB
Auburn Bancorp (PK)
NYSE
GMRE-A
Global Med REIT
COIN
IGGBP
IGNITE
COIN
DARUSD
Dalarnia
NYSE
PRPC.U
CC Neuberger Principal H...
NASDAQ
TFSL
TFS Financial
AMEX
MIMO.WS.A
Airspan Networks
Delayed Upgrade Clock
ADVFN Logo
México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios